Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Adjuvant capecitabine did not significantly improve outcomes for breast cancer patients

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.18
Views: 631

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

Dr Miguel Martin gives a press conference at SABCS 2018 about the randomised, phase II GEICAM/CIBOMA trial, which indicated that treating patients with early-stage, triple-negative breast cancer with the chemotherapy agent capecitabine following surgery and standard chemotherapy did not significantly improve outcomes.

Watch his interview with ecancer here.

Read more about this work here.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation